tbuckley/cabot-search huggingface dataset:
Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis
Authors: Fei Xie, Yawei Li, Miao Wang, Chao Huang, Dan Tao, Fuxin Zheng, Hui Zhang, Fuqing Zeng, Xingyuan Xiao, Guosong Jiang
Journal: Molecular Cancer (2018)

Circular RNAs (circRNAs) are a new member of noncoding RNAs (ncRNAs) that have recently been described as key regulators of gene expression. Our previous study had identified the negative correlation between circHIPK3 and bladder cancer grade, invasion, as well as lymph node metastasis. However, the roles of circRNAs in cellular proliferation in bladder cancer remain largely unknown. We had analyzed circRNA high-throughout sequencing from human tissues and determined bladder cancer related circRNA-3 (BCRC-3, GenBank: KU921434.1) as a new candidate circRNA derived from PSMD1 gene. The expression levels of circRNAs, mRNAs and miRNAs in human tissues and cells were detected by quantitative real-time PCR (qRT-PCR). The effects of BCRC-3 on cancer cells were explored by transfecting with plasmids in vitro and in vivo. RNA pull down assay, luciferase reporter assay and fluorescence in situ hybridization were applied to verify the interaction between BCRC-3 and microRNAs. Anticancer effects of methyl jasmonate (MJ) were measured by flow cytometry assay, western blot and qRT-PCR. BCRC-3 was lowly expressed in bladder cancer tissues and cell lines. Proliferation of BC cells was suppressed by ectopic expression of BCRC-3 in vitro and in vivo. Mechanistically, overexpression of BCRC-3 induced the expression of cyclin-dependent kinase inhibitor 1B (p27). Importantly, BCRC-3 could directly interact with miR-182-5p, and subsequently act as a miRNA sponge to promote the miR-182-5p-targeted 3'UTR activity of p27. Furthermore, MJ significantly increased the expression of BCRC-3, resulting in an obvious up-regulation of p27. BCRC-3 functions as a tumor inhibitor to suppress BC cell proliferation through miR-182-5p/p27 axis, which would be a novel target for BC therapy.
Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma
Authors: Yan Chen, Hai-Ning Chen, Kui Wang, Lu Zhang, Zhao Huang, Jiayang Liu, Zhe Zhang, Maochao Luo, Yunlong Lei, Yong Peng, Zong-Guang Zhou, Yuquan Wei, Canhua Huang
Journal: Journal of Hepatology (2018)
Mitochondria and plasma membrane dual-targeted chimeric peptide for single-agent synergistic photodynamic therapy
Authors: Hong Cheng, Rong-Rong Zheng, Gui-Ling Fan, Jing-Hao Fan, Lin-Ping Zhao, Xue-Yan Jiang, Bin Yang, Xi-Yong Yu, Shi-Ying Li, Xian-Zheng Zhang
Journal: Biomaterials (2018)
The Patient Experience and Use of Telemetry Monitoring
Authors: Ankush K. Bansal, Mary E. Lacy, Surfael Tsega
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Endocrinology of Transgender Medicine
Authors: Guy T’Sjoen, Jon Arcelus, Louis Gooren, Daniel T Klink, Vin Tangpricha
Journal: Endocrine Reviews (2018)

Gender-affirming treatment of transgender people requires a multidisciplinary approach in which endocrinologists play a crucial role. The aim of this paper is to review recent data on hormonal treatment of this population and its effect on physical, psychological, and mental health. The Endocrine Society guidelines for transgender women include estrogens in combination with androgen-lowering medications. Feminizing treatment with estrogens and antiandrogens has desired physical changes, such as enhanced breast growth, reduction of facial and body hair growth, and fat redistribution in a female pattern. Possible side effects should be discussed with patients, particularly those at risk for venous thromboembolism. The Endocrine Society guidelines for transgender men include testosterone therapy for virilization with deepening of the voice, cessation of menses, and increases of muscle mass and facial and body hair. Owing to the lack of evidence, treatment of gender nonbinary people should be individualized. Young people may receive pubertal suspension, consisting of GnRH analogs, later followed by sex steroids. Options for fertility preservation should be discussed before any hormonal intervention. Morbidity and cardiovascular risk with cross-sex hormones is unchanged among transgender men and unclear among transgender women. Sex steroid–related malignancies can occur but are rare. Mental health problems such as depression and anxiety have been found to reduce considerably following hormonal treatment. Future studies should aim to explore the long-term outcome of hormonal treatment in transgender people and provide evidence as to the effect of gender-affirming treatment in the nonbinary population.
THREE-DIMENSIONAL MULTICOLOUR LINEAGE TRACING OF INTRINSIC BRAIN TUMOUR MODELS
Authors: James Innes, Tian Yu, Loredana Guglielmi, Sebastian Brandner
Journal: Neuro-Oncology (2018)

Multicolour lineage tracing has provided striking demonstrations of stem cell tissue maintenance and development. Our objective is to gain insight into histogenesis, clonal expansion and migration of intrinsic brain tumours. We aim to investigate intratumoral heterogeneity through the identification of differently labelled clones but also the impact of different genetic lesions on tumour propagation. Combining multicolour tracing with advanced tissue clearing and image analysis we will interrogate these parameters in three-dimensions (3D). Rosa26-Confetti and Brainbow mice were crossed into lines containing different combinations of floxed tumour suppressor alleles. In this model, recombination is targeted to neural stem cells by intraventricular injection of a retrovirus expressing Cre recombinase and PDGFβ. Using this method multicolour tumours with histological hallmarks of human gliomas can be induced within 4 – 6 weeks. This rapid induction model will be used for the development of the methodology, including 3D image acquisition and image processing. Traditional sectioning and passive clarity (PACT) are used to prepare tissue for 2D and 3D imaging. This model of primary murine brain tumours will be complemented by a xenogafting approach, using genetically characterised multiple human glioma initiating cell lines, genetically labelled with lineage tracing vectors. Tumour formation will be assessed with methods established using the retroviral model. Retroviral injections induce tumour formation currently at an efficiency of ~50%. On frozen sections multiple colours are visible within all tumours representing the identification of different genetic clones. Tissue clearing has been successfully employed to image 3D volumes. The presence of differentially labelled cells in our tumour model opens the potential for assessing clonal expansion and tumour heterogeneity.
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
Authors: Paul W. Harms, Kelly L. Harms, Patrick S. Moore, James A. DeCaprio, Paul Nghiem, Michael K. K. Wong, Isaac Brownell
Journal: Nature Reviews Clinical Oncology (2018)

Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer associated with advanced age and immunosuppression. Over the past decade, an association has been discovered between MCC and either integration of the Merkel cell polyomavirus, which likely drives tumorigenesis, or somatic mutations owing to ultraviolet-induced DNA damage. Both virus-positive and virus-negative MCCs are immunogenic, and inhibition of the programmed cell death protein 1 (PD-1)–programmed cell death 1 ligand 1 (PD-L1) immune checkpoint has proved to be highly effective in treating patients with metastatic MCC; however, not all patients have a durable response to immunotherapy. Despite these rapid advances in the understanding and management of patients with MCC, many basic, translational and clinical research questions remain unanswered. In March 2018, an International Workshop on Merkel Cell Carcinoma Research was held at the US National Cancer Institute, at which academic, government and industry experts met to identify the highest-priority research questions. Here, we review the biology and treatment of MCC and report the consensus-based recommendations agreed upon during the workshop. Merkel cell carcinoma (MCC) is a rare and aggressive form of nonmelanoma skin cancer. The availability of immune checkpoint inhibition has improved the outcomes of a subset of patients with MCC, although many unmet needs continue to exist. In this Consensus Statement, the authors summarize developments in our understanding of MCC while also providing consensus recommendations for future research.
Author Correction: MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation
Authors: Sandra R. Bacman, Johanna H. K. Kauppila, Claudia V. Pereira, Nadee Nissanka, Maria Miranda, Milena Pinto, Sion L. Williams, Nils-Göran Larsson, James B. Stewart, Carlos T. Moraes
Journal: Nature Medicine (2018)
Hydrochlorothiazide and the Risk of Malignant Melanoma—Reply
Authors: Anton Pottegård, David Gaist
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
USING QUALITATIVE RESEARCH METHODS TO OPTIMISE RECRUITMENT: THE ROAM (RADIATION VERSUS OBSERVATION FOLLOWING SURGICAL RESECTION OF ATYPICAL MENINGIOMA) INFORMATION STUDY
Authors: Michael Jenkinson, Frances Sherratt, Brian Haylock, Mohsen Javadpour, Bridget Young
Journal: Neuro-Oncology (2018)

ROAM is a randomised controlled trial comparing radiation to observation following complete surgical resection of atypical meningioma. We embedded a qualitative sub-study within ROAM with the aim of optimising patient recruitment. Audio-recorded recruitment consultation (N=25), and semi-structured interviews with clinicians (N=14) and patients (N=22), including decliners and consenters. Analysis of transcribed audio-recordings was informed by content and thematic analysis. Analysis identified areas where communication was problematic. Giving patients their pathology results immediately before discussing ROAM left them overwhelmed and unable to absorb trial information. Interviewed clinicians were keen to participate in ROAM but some indicated concerns regarding the eligibility of patients at either ends of the age spectrum, believing such patients may not tolerate radiotherapy well. Clinicians’ presentation of the trial arms in consultations often lacked balance (emphasising the process and side effects of radiotherapy but providing limited information regarding active monitoring) and their terminology inadvertently led to misinterpretations among some patients. When interviewed, several patients struggled to see the logic of radiotherapy after hearing in previous consultations that further treatment was unnecessary. Patients who declined ROAM were concerned about the side effects of radiotherapy and viewed it as burdensome; many struggled to interpret key details of ROAM due to problematic communication. Embedded qualitative studies can identify barriers to recruitment in neuro-oncology trials and suggest ways to address these. We have amended the patient information leaflet, provided workshops and a webinar for oncologists and surgeons to enhance communication about ROAM, with the aim of optimising patient recruitment. Surgeons can aid recruitment by explaining to patients before surgery that they may be eligible for ROAM, if following surgery, they are diagnosed with atypical meningioma.
Wireless bioresorbable electronic system enables sustained nonpharmacological neuroregenerative therapy
Authors: Jahyun Koo, Matthew R. MacEwan, Seung-Kyun Kang, Sang Min Won, Manu Stephen, Paul Gamble, Zhaoqian Xie, Ying Yan, Yu-Yu Chen, Jiho Shin, Nathan Birenbaum, Sangjin Chung, Sung Bong Kim, Jawad Khalifeh, Daniel V. Harburg, Kelsey Bean, Michael Paskett, Jeonghyun Kim, Zohny S. Zohny, Seung Min Lee, Ruoyao Zhang, Kaijing Luo, Bowen Ji, Anthony Banks, Hyuck Mo Lee, Younggang Huang, Wilson Z. Ray, John A. Rogers
Journal: Nature Medicine (2018)
MIRNA EXPRESSION AND ITS FUNCTIONAL EFFECTS IN PAEDIATRIC ASTROCYTOMA
Authors: Stuart Smith, Maria de los Angeles Estevez-Cebrero, Hazel Anne Rogers, Jennifer Helen Ward, Donald Cormac Macarthur, Richard Grundy
Journal: Neuro-Oncology (2018)

Micro-Ribonucleic acids (miRNAs) are short non-protein coding RNAs involved in post-transcriptional regulation of genes by targeting the 3’ region of mRNAs. They have been associated with dysregulation of oncogenes and tumour suppressors (i.e. Myc and PTEN) and signalling pathways (i.e. PDGF and EGF) in many human cancers including adult high grade glioma (HGG). However, limited work has been published about their role in paediatric astrocytoma. Here, we examine the miRNA profile of paediatric astrocytomas of different grades, their correlation to survival and micro-vascularity and their function in proliferation, invasion and migration. The Nanostring nCounter miRNA array system analysed the expression levels of 665 miRNA sequences in 116 samples (101 astrocytoma tumours, 2 normal brain samples and 13 cell lines). Validation of selected miRNAs and their role in survival and micro-vascularity was studied by qPCR and immunohistochemistry. The functional effect of these miRNAs was evaluated by knock-down/knock-up of the sequences into the paediatric HGG cell lines SF-188 and KNS42 by transient transfection followed by Presto blue assay (assessing proliferation) and transwell assay in the presence (for invasion) or absence (for migration) of extra-cellular proteins. 551 miRNAs were significantly expressed between HGG, low grade glioma (LGG) and normal brain. 89 of them exhibited fold-differences higher than 3, including miR-451, miR-149 and miR-21. The latter has known oncogenic effects in adult HGG and we also observed that its overexpression in SF-188 and KNS42 resulted in significant increased proliferation of more than double after 5 days. The comparison between HGG and LGG displayed differences in the expression of 10 miRNAs, with miR-34a down-regulated in HGG and correlating to loss of its chromosomal locus in 12–13% of tumours. Specific miRNA profile signature of paediatric astrocytomas of different grades could potentially be used for prognosis and for identifying personalised therapeutic targets.
Abstract 20568: Increased MicroRNA-130a in Patients With Ventricular Tachycardia and End-Stage Heart Failure
Authors: Tyler Calway, Trevor Bak, Gene Kim
Journal: Circulation (2014)

Introduction: MicroRNAs (miRs) are endogenous ~22 nucleotide RNA molecules that are critical regulators of diverse biological processes; however, studies of miRs and arrhythmia remain sparse in human hearts. Cardiac arrhythmias result in extensive morbidity and mortality and significantly affect the quality of life of patients. We recently reported on the role of miR-130a in regulation of the gap junction protein, connexin43 (Cx43). Increased expression of miR-130a in mice resulted in both atrial arrhythmias and ventricular tachycardia (VT) via a loss of cardiac Cx43. We aimed to determine whether levels of miR-130a in explanted heart tissue from human patients correlated with the presence of ventricular tachyarrhythmias. Methods: A prospective study was performed to determine the association between miR-130a levels and VT. Subjects were enrolled at the time of listing for transplantation at the University of Chicago between June 2013 and June 2014. Patients with high arrhythmia burden were defined as: 1)...
Questions Regarding the Value of CCL21 as a Potential Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann‐Vold et al
Authors: Ren‐Peng Zhou, Xin Wei, Gang‐Gang Ma, Fei Zhu, Fei‐Hu Chen, Wei Hu
Journal: Arthritis & Rheumatology (2018)
Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities
Authors: Matthew P. Humphries, Stephen McQuaid, Stephanie G. Craig, Victoria Bingham, Perry Maxwell, Manisha Maurya, Fiona McLean, James Sampson, Patricia Higgins, Christine Greene, Jacqueline James, Manuel Salto-Tellez
Journal: Journal of Thoracic Oncology (2018)

Patient suitability to anti-programmed death ligand 1 (PD-L1) immune checkpoint inhibition is key to the treatment of NSCLC. We present, applied to PD-L1 testing: a comprehensive cross-validation of two immunohistochemistry (IHC) clones; our descriptive experience in diagnostic reflex testing; the concordance of IHC to in situ RNA (RNA-ISH); and application of digital pathology.
We should scrap the internal market
Authors: Malcolm Segall
Journal: BMJ (2018)

Modi and colleagues make a strong case against the private sector market in the NHS.1 They are absolutely correct. But NHS privatisation is a secondary cancer; the primary tumour is the internal market.

The internal market has turned our public hospitals into businesses in which, when there is a conflict between financial health and patients’ health, financial health trumps. The Mid Staffordshire …
Intensive inpatient neuro-oncology rehabilitation- a new model of care: an evaluation of the first 6 months of this unique service at St. Bartholomew’s hospital
Authors: Ms Tara Lacey, Ms Jo Wade, Lindsay Farthing, Ms Hannah Lowe, Dr Rachel Lewis
Journal: Neuro-Oncology (2018)

Due to advances in cancer treatments, increasing numbers of patients are surviving with brain and spinal tumours. However, patients often have complex neuro-pathology with resulting impairments, and require specialist rehabilitation. With limited in-patient rehab units, patients frequently get stuck in acute settings, reducing patient flow. Alternatively patients are discharged with a high level of dependence and limited rehabilitation potential. A new Neuro-oncology Rehab Service (NORS) was introduced at Barts, in collaboration with Macmillan Cancer Support, to provide intensive neuro-oncology rehabilitation in the acute setting, for 2 years initially. AIMS: 1)To improve patient experience, functional outcomes, and quality of life. 2) to improve patient flow through acute services. 3) to improve links with post-acute rehabilitation services. 4) To enhance patient management by the MDT. The service launched in July 2017. A dedicated occupational therapist and physiotherapist were appointed to deliver rehabilitation to patients referred for this service, with dedicated inpatient beds. Within the first 6 months, intensive neuro-rehabilitation was delivered to 25 patients. The service was bench-marked against acute oncology rehabilitation services, post-acute in-patient, and community rehabilitation services. Data were collected and reviewed using outcome measures including the UK FIM+FAM. For all patients who remained under the NORS, improvements were seen in functional outcomes, neurological impairments, quality of life, length of stay, and all patients reported a positive patient experience. The service was well received by the MDT, and there were positive financial implications through reducing patients’ care requirements. The service has shown positive early results, meeting its aims. There is potential for this service to be introduced in any acute setting. Thorough data collection and robust analysis should be completed for the remainder of the project term to support service continuation. Data should aim to support formulation of guidelines regarding therapy recommendations for neuro-oncology patients.
Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study
Authors: Martee L. Hensley, Danielle Enserro, Helen Hatcher, Petronella B. Ottevanger, Anders Krarup-Hansen, Jean-Yves Blay, Cyril Fisher, Katherine M. Moxley, Shashikant B. Lele, Jayanthi S. Lea, Krishnansu S. Tewari, Premal H. Thaker, Oliver Zivanovic, David M. O’Malley, Katina Robison, David S. Miller
Journal: Journal of Clinical Oncology (2018)

Purpose We conducted a randomized phase III trial to determine whether adjuvant chemotherapy improves survival in women with uterine leiomyosarcoma. Methods Women with uterus-confined, high-grade leiomyosarcoma who were confirmed disease free by imaging were randomly assigned to four cycles of gemcitabine plus docetaxel, followed by four cycles of doxorubicin, or to observation. All were followed for evidence of recurrence. The primary end point was overall survival (OS). Results With international collaboration, 38 of the targeted accrual of 216 patients were enrolled, after which the study was closed by the National Cancer Institute for accrual futility. Twenty patients were assigned to chemotherapy, 18 to observation. Among the 17 patients treated with at least one cycle of chemotherapy, grade 3 or 4 toxicities were observed in 47%; among the 18 patients assigned to observation, one had grade 3 hypertension. There were six deaths (chemotherapy, n = 5; observation, n = 1), all due to disease. The restricted mean survival time for OS was estimated as 34.3 months (95% CI, 25.3 to 43.3 months) in the chemotherapy arm and as 46.4 months (95% CI, 43.6 to 49.1 months) in the observation arm. There were eight recurrences in each arm. The restricted mean survival time for recurrence-free survival was estimated as 18.1 (95% CI, 14.2 to 22.0) months in the chemotherapy arm and as 14.6 months (95% CI, 10.3 to 19.0 months) in the observation arm. Neither survival outcome comparison was considered statistically robust, due to the small sample size. Conclusion Despite international collaboration to test the role of adjuvant chemotherapy in uterine-confined leiomyosarcoma, this study was closed for accrual futility. Although the sample size precludes robust statistical comparison, observed OS and recurrence-free survival data do not show superior outcomes with adjuvant chemotherapy.